Gynecologic Surgery
Conditions
Interventions
Group C:The Control Group (Group C) received bilateral transversus abdominis plane blocks with 40 mL total volume of 0.375% ropivacaine in normal saline solution.
Group S1:Group S1 received bilateral transversus abdominis plane blocks with a 40-mL solution containing 0.375% ropivacaine, 0.25 mg/kg esketamine, and normal saline.
Group S2:Group S1 received bilateral transversus abdominis plane blocks with a 40-mL solution containing 0.375% ropivacaine, 0.5 mg/kg esketamine, and normal saline.
Sponsors
Hainan General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. American Society of Anesthesiologists (ASA) Physical Status Classification I-III; 2. Body Mass Index (BMI) 18.5 ~ 30.0 kg/m²; 3. Aged 18-65 years; 4. Scheduled for elective laparoscopic total hysterectomy; 5. Capable of comprehending study procedures and voluntarily providing informed consent.
Exclusion criteria
Exclusion criteria: 1. Declined participation 2. Contraindications to general anesthesia or history of adverse events under general anesthesia 3. Known allergy or contraindication to any study medication 4. Contraindications to nerve blockade (local anesthetic allergy, skin breakdown/infection at puncture site, coagulopathy) 5. BMI 30 kg/m² 6. Severe systemic organ dysfunction 7. Severe dementia/language barriers precluding outcome assessment 8. Regular use of psychotropic/analgesic medications within 3 months 9. Contraindications to esketamine (significant risk of elevated blood pressure/intracranial pressure, esketamine hypersensitivity, psychiatric disorders) 10. Pregnancy or lactation 11. History of substance abuse or chronic use of anesthetics/sedatives/analgesics 12. Participation in other clinical trials within 2 months 13. History of chronic pain conditions 14. Other contraindications per investigator's judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recovery Quality Scores (QoR-15 scale assessments recorded at preoperative day 1, postoperative day 1 [POD1], and postoperative day 2 [POD2]); | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS Scores at Rest and on Movement;IL-6;Total Opioid Consumption ; | — |
Countries
China
Contacts
Public ContactRenbang Guo; Duozhi Wu
Hainan General Hospital
Outcome results
None listed